Antonella Loperfido, Claudio Montuori, Marco Caminati, Niccolò Gori, Leandro Maria D'Auria, Gianluca Bellocchi, Carlo Cavaliere, Daniela Lucidi, Moffa Antonio, Eugenio De Corso
{"title":"减少针对2型炎症的生物制剂剂量的策略:系统综述。","authors":"Antonella Loperfido, Claudio Montuori, Marco Caminati, Niccolò Gori, Leandro Maria D'Auria, Gianluca Bellocchi, Carlo Cavaliere, Daniela Lucidi, Moffa Antonio, Eugenio De Corso","doi":"10.1007/s11882-025-01214-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>This review evaluates current evidence on tapering strategies for anti-type 2 biologics in chronic inflammatory diseases. Given the need for long-term treatment, optimizing dosage without compromising efficacy is essential for sustainable disease management.</p><p><strong>Recent findings: </strong>Biologic dose reduction strategies, such as tapering, de-escalation, dose spacing and interval dose prolongation, are increasingly explored in various type 2 inflammatory diseases, particularly in real-life settings. Studies have shown variable outcomes depending on disease type, patient characteristics, and tapering methods. Nineteen studies met inclusion criteria in this systematic review. The evidence supports the feasibility of dose tapering, especially for dupilumab, in maintaining disease control while reducing drug exposure. However, standardized tapering protocols and clear patient selection criteria remain lacking. Further prospective, controlled studies are needed to define optimal, safe, and personalized de-escalation strategies for long-term management of type 2 inflammatory diseases.</p>","PeriodicalId":55198,"journal":{"name":"Current Allergy and Asthma Reports","volume":"25 1","pages":"32"},"PeriodicalIF":4.6000,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Strategies for Tapering the Dosage of Biologics Targeting Type 2 Inflammation: A Systematic Review.\",\"authors\":\"Antonella Loperfido, Claudio Montuori, Marco Caminati, Niccolò Gori, Leandro Maria D'Auria, Gianluca Bellocchi, Carlo Cavaliere, Daniela Lucidi, Moffa Antonio, Eugenio De Corso\",\"doi\":\"10.1007/s11882-025-01214-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose of review: </strong>This review evaluates current evidence on tapering strategies for anti-type 2 biologics in chronic inflammatory diseases. Given the need for long-term treatment, optimizing dosage without compromising efficacy is essential for sustainable disease management.</p><p><strong>Recent findings: </strong>Biologic dose reduction strategies, such as tapering, de-escalation, dose spacing and interval dose prolongation, are increasingly explored in various type 2 inflammatory diseases, particularly in real-life settings. Studies have shown variable outcomes depending on disease type, patient characteristics, and tapering methods. Nineteen studies met inclusion criteria in this systematic review. The evidence supports the feasibility of dose tapering, especially for dupilumab, in maintaining disease control while reducing drug exposure. However, standardized tapering protocols and clear patient selection criteria remain lacking. Further prospective, controlled studies are needed to define optimal, safe, and personalized de-escalation strategies for long-term management of type 2 inflammatory diseases.</p>\",\"PeriodicalId\":55198,\"journal\":{\"name\":\"Current Allergy and Asthma Reports\",\"volume\":\"25 1\",\"pages\":\"32\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2025-07-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Allergy and Asthma Reports\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11882-025-01214-9\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Allergy and Asthma Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11882-025-01214-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
Strategies for Tapering the Dosage of Biologics Targeting Type 2 Inflammation: A Systematic Review.
Purpose of review: This review evaluates current evidence on tapering strategies for anti-type 2 biologics in chronic inflammatory diseases. Given the need for long-term treatment, optimizing dosage without compromising efficacy is essential for sustainable disease management.
Recent findings: Biologic dose reduction strategies, such as tapering, de-escalation, dose spacing and interval dose prolongation, are increasingly explored in various type 2 inflammatory diseases, particularly in real-life settings. Studies have shown variable outcomes depending on disease type, patient characteristics, and tapering methods. Nineteen studies met inclusion criteria in this systematic review. The evidence supports the feasibility of dose tapering, especially for dupilumab, in maintaining disease control while reducing drug exposure. However, standardized tapering protocols and clear patient selection criteria remain lacking. Further prospective, controlled studies are needed to define optimal, safe, and personalized de-escalation strategies for long-term management of type 2 inflammatory diseases.
期刊介绍:
The aim of Current Allergy and Asthma Reports is to systematically provide the views of highly selected experts on current advances in the fields of allergy and asthma and highlight the most important papers recently published. All reviews are intended to facilitate the understanding of new advances in science for better diagnosis, treatment, and prevention of allergy and asthma.
We accomplish this aim by appointing international experts in major subject areas across the discipline to review select topics emphasizing recent developments and highlighting important new papers and emerging concepts. We also provide commentaries from well-known figures in the field, and an Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research. Over a one- to two-year period, readers are updated on all the major advances in allergy and asthma.